Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ALKS

ALKS - Alkermes PLC Stock Price, Fair Value and News

24.50USD-0.31 (-1.25%)Market Closed

Market Summary

ALKS
USD24.50-0.31
Market Closed
-1.25%

ALKS Alerts

  • Big jump in Earnings (Y/Y)

ALKS Stock Price

View Fullscreen

ALKS RSI Chart

ALKS Valuation

Market Cap

4.2B

Price/Earnings (Trailing)

9.66

Price/Sales (Trailing)

2.43

EV/EBITDA

6.94

Price/Free Cashflow

10.65

ALKS Price/Sales (Trailing)

ALKS Profitability

EBT Margin

28.85%

Return on Equity

34.62%

Return on Assets

20.45%

Free Cashflow Yield

9.39%

ALKS Fundamentals

ALKS Revenue

Revenue (TTM)

1.7B

Rev. Growth (Yr)

21.83%

Rev. Growth (Qtr)

-7.18%

ALKS Earnings

Earnings (TTM)

434.4M

Earnings Growth (Yr)

188.01%

Earnings Growth (Qtr)

-67.34%

Breaking Down ALKS Revenue

52 Week Range

24.2733.71
(Low)(High)

Last 7 days

2.7%

Last 30 days

1.3%

Last 90 days

-13.7%

Trailing 12 Months

-21.9%

How does ALKS drawdown profile look like?

ALKS Financial Health

Current Ratio

3.2

Debt/Equity

0.23

Debt/Cashflow

1.55

ALKS Investor Care

Shares Dilution (1Y)

1.87%

Diluted EPS (TTM)

2.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20241.7B000
20231.1B1.5B1.6B1.7B
20221.2B1.2B1.1B1.1B
20211.0B1.1B1.1B1.2B
20201.2B1.2B1.2B1.0B
20191.1B1.1B1.1B1.2B
2018936.7M1.0B1.1B1.1B
2017780.7M804.4M841.5M903.4M
2016623.9M667.7M695.3M745.7M
2015649.8M647.7M640.4M628.3M
2014563.1M577.9M598.1M618.8M
2013575.5M561.9M577.8M596.3M
2012390.0M480.3M532.3M542.6M
2011186.6M219.3M242.1M331.8M
2010178.3M0181.1M183.9M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Alkermes PLC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 09, 2024
alva emily peterson
acquired
-
-
3,871
-
Jun 09, 2024
alva emily peterson
sold (taxes)
-22,236
23.91
-930
-
Jun 08, 2024
wright christopher i
sold (taxes)
-18,960
23.91
-793
-
Jun 08, 2024
wright christopher i
acquired
-
-
3,301
-
Mar 18, 2024
nichols christian todd
sold
-292,740
28.1021
-10,417
svp, chief commercial officer
Feb 27, 2024
parisi samuel joseph
sold
-75,874
29.65
-2,559
vp, finance (interim pao)
Feb 23, 2024
gaffin david joseph
acquired
-
-
7,689
evp, clo, alkermes, inc.
Feb 23, 2024
parisi samuel joseph
acquired
-
-
2,283
vp, finance (interim pao)
Feb 23, 2024
jackson blair curtis
sold (taxes)
-114,732
29.57
-3,880
evp, chief operating officer
Feb 23, 2024
landine michael j
acquired
-
-
4,077
svp, corp dev., alkermes, inc.

1–10 of 50

Which funds bought or sold ALKS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
added
23.25
1,250
15,093
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
sold off
-100
-1,506,000
-
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
26.18
1,125,000
5,990,000
0.05%
May 24, 2024
Cetera Investment Advisers
new
-
273,245
273,245
-%
May 22, 2024
BURNEY CO/
reduced
-87.04
-4,277,140
619,280
0.02%
May 22, 2024
Beck Bode, LLC
new
-
738,253
738,253
0.15%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.32
333,218
869,218
0.11%
May 16, 2024
Tidal Investments LLC
new
-
440,754
440,754
0.01%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-30.23
-948,698
2,023,700
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.09
-345,262
4,333,370
-%

1–10 of 45

Are Funds Buying or Selling ALKS?

Are funds buying ALKS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALKS
No. of Funds

Unveiling Alkermes PLC's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
12.56%
20,955,454
SC 13G/A
Feb 08, 2024
wellington management group llp
9.13%
15,241,470
SC 13G
Jan 24, 2024
state street corp
5.60%
9,352,970
SC 13G
Jan 08, 2024
blackrock inc.
18.0%
30,021,312
SC 13G/A
Aug 24, 2023
sarissa capital management lp
997%
8,323,400
SC 13D/A
Jun 28, 2023
sarissa capital management lp
-
0
SC 13D/A
Jun 27, 2023
sarissa capital management lp
-
0
SC 13D/A
Jun 23, 2023
sarissa capital management lp
-
0
SC 13D/A
Jun 21, 2023
sarissa capital management lp
-
0
SC 13D/A
Jun 16, 2023
sarissa capital management lp
-
0
SC 13D/A

Recent SEC filings of Alkermes PLC

View All Filings
Date Filed Form Type Document
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading

Peers (Alternatives to Alkermes PLC)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
350.0B
85.6B
-3.94% -10.00%
9.1
4.09
5.68% 202.39%
327.6B
61.4B
0.54% 19.05%
142.08
5.34
6.11% -82.30%
160.0B
29.5B
-4.21% 34.20%
42.52
5.42
12.76% -52.47%
156.6B
35.0B
-2.61% -29.78%
134.79
4.47
-26.40% -92.03%
79.1B
27.4B
-6.10% -18.51%
163.34
2.88
1.51% -91.32%
19.5B
16.0B
1.81% 133.24%
-39.52
1.22
7.23% 71.10%
MID-CAP
4.2B
1.7B
1.31% -21.88%
9.66
2.43
54.01% 364.56%
3.7B
4.6B
-9.61% -18.87%
-484.91
0.82
-0.06% 94.55%
2.3B
9.0B
-13.20% -15.57%
-4.97
0.25
10.01% -27.45%
2.0B
676.2M
-1.62% -15.25%
12.84
2.94
30.38% 66.04%
SMALL-CAP
1.3B
743.2M
-16.75% 6.10%
-3.83
1.81
24.65% 80.36%
22.8M
1.3M
-2.94% -47.62%
-3.08
17.54
-98.14% -104.71%
16.7M
89.6M
-19.67% -19.01%
-1.17
0.19
287.27% -129.41%
2.5M
21.5M
-5.26% -89.66%
-0.32
0.11
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Alkermes PLC News

Latest updates
Yahoo Canada Shine On11 Jun 202412:07 pm

Alkermes PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-7.2%350377381617288305252276279324294304251280265248246413255280223
Costs and Expenses41.4%307217337378299189313311305195314299268311276281284423309316299
  S&GA Expenses24.9%180144169205168143153150145149136139125146128132133154149155141
  R&D Expenses1260.6%68.00-5.8397.0010164.00-16.5510093.0096.00-17.2311897.0092.0011295.0094.0093.00198108104103
EBITDA Margin5.0%0.34*0.32*0.28*0.23*0.05*0.05*0.06*0.09*0.12*0.15*0.01*0.03*---------
Interest Expenses-1.3%6.006.006.006.005.005.004.002.002.002.002.002.004.002.002.002.003.003.003.004.004.00
Income Taxes108.2%8.00-97.29-0.403.001.0018.00-3.39-3.11-9.102.002.003.004.001.002.004.007.003.00-0.982.00-3.85
Earnings Before Taxes-71.4%47.0016447.00240-11.33114-67.37-33.25-45.00127-26.536.00-18.65-41.652.00-25.76-31.32-2.56-53.86-40.39-100
EBT Margin9.1%0.29*0.26*0.22*0.16*-0.03*-0.03*-0.02*0.02*0.05*0.07*-0.07*-0.05*---------
Net Income-67.3%37.0011348.00237-41.84-28.25-63.97-30.14-35.901.00-28.992.00-22.42-42.64-0.13-29.43-38.65-5.35-52.88-41.99-96.40
Net Income Margin17.7%0.25*0.21*0.13*0.07*-0.15*-0.14*-0.11*-0.08*-0.05*-0.04*-0.08*-0.06*---------
Free Cashflow-85.8%13.0090.0085.00206-28.16-8.98-9.85-12.2714.0022.0078.0027.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-0.6%2,1242,1362,2792,1871,9231,9641,9421,9571,9782,0241,9951,9381,8781,9501,8771,8021,8261,8051,7581,7521,757
  Current Assets-1.1%1,4691,4861,4651,3971,1101,1301,0541,0461,0151,0621,0531,0381,0061,1111,025947913962998995963
    Cash Equivalents-8.0%421457648666321292264255283338310258205273241189176204261196225
  Inventory6.4%19818619218918518116615615515013913613412612311610910210195.0093.00
  Net PPE-1.0%225227328324321223326337337341341344346350355362363362341326320
  Goodwill0%83.0083.0093.0093.0093.0083.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.0093.00
Liabilities-6.9%869934924907917920899875902912899840827883792740763720690661654
  Current Liabilities-11.8%459520503487493498470439462471453383366438378321340391370334328
  Long Term Debt-0.2%287288288289290290291292292293293294295272273273274274275275276
    LT Debt, Current0%3.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.00
    LT Debt, Non Current-0.2%287288288289290290291292292293293294295272273273274274275275276
Shareholder's Equity4.3%1,2551,2031,3561,2801,0061,0441,0431,0821,0751,1131,0961,0981,0511,0671,0841,0621,0631,0851,0681,0911,102
  Retained Earnings2.7%-1,306-1,343-1,456-1,504-1,741-1,699-1,671-1,607-1,576-1,541-1,541-1,512-1,515-1,492-1,450-1,450-1,420-1,381-1,376-1,323-1,281
  Additional Paid-In Capital1.6%2,7812,7373,0032,9762,9392,9132,8862,8582,8192,7982,7792,7492,7032,6862,6602,6362,6092,5862,5632,5332,503
Shares Outstanding1.3%169167167166165164164164162161161160---------
Float----4,792---4,838---3,918---3,058---3,508-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-80.3%21,108107,23799,708215,710-21,3021,047625-2,30621,67831,02182,77733,063-45,14667,34360,203-4,432-40,27242,07030,972-23,17722,212
  Share Based Compensation26.7%32,75525,84323,91528,50422,64326,48326,05123,37718,34319,01925,60027,55215,45124,88522,62022,84619,81321,38726,72928,24524,616
Cashflow From Investing-90.4%-39,951-20,982-119,359120,84872,85027,7408,898-40,538-60,641-742-31,7073,977-37,732-35,097-8,22714,35117,492-101,47131,594-7,253-64,703
Cashflow From Financing93.5%-17,873-276,4971,5677,836-22,620-271-21214,933-16,024-3,1791,03316,27314,945-151-1123,016-4,9241,7462,9061,150963
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ALKS Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
REVENUES:  
Total revenues$ 350,372$ 287,595
EXPENSES:  
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)58,64458,164
Research and development67,61163,770
Selling, general and administrative179,749167,833
Amortization of acquired intangible assets1,0598,800
Total expenses307,063298,567
OPERATING INCOME (LOSS) FROM CONTINUING OPERATIONS43,309(10,972)
OTHER INCOME (EXPENSE), NET:  
Interest income9,3994,966
Interest expense(5,978)(5,288)
Other income (expense), net182(39)
Total other income (expense), net3,603(361)
INCOME (LOSS) BEFORE INCOME TAXES46,912(11,333)
INCOME TAX PROVISION7,964717
NET INCOME (LOSS) FROM CONTINUING OPERATIONS38,948(12,050)
DISCONTINUED OPERATIONS, NET OF TAX(2,120)(29,795)
NET INCOME (LOSS)$ 36,828$ (41,845)
EARNINGS (LOSS) PER ORDINARY SHARE:  
Earnings (loss) per share from continuing operations - basic$ 0.23$ (0.07)
Loss per share from discontinued operations - basic(0.01)(0.18)
Earnings (loss) per share - basic0.22(0.25)
Earnings (loss) per share from continuing operations - diluted0.23(0.07)
Loss per share from discontinued operations - diluted(0.01)(0.18)
Earnings (loss) per share - diluted$ 0.21$ (0.25)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:  
Basic167,984165,085
Diluted172,981165,085
COMPREHENSIVE INCOME (LOSS):  
Net income (loss)$ 36,828$ (41,845)
Holding (loss) gain, net of a tax (benefit) provision of $(75) and $488, respectively(491)2,760
COMPREHENSIVE INCOME (LOSS)36,337(39,085)
Product sales, net  
REVENUES:  
Total revenues233,536214,727
Manufacturing and royalty revenues  
REVENUES:  
Total revenues116,83372,862
Research and development revenue  
REVENUES:  
Total revenues$ 3$ 6

ALKS Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
CURRENT ASSETS:  
Cash and cash equivalents$ 420,753$ 457,469
Receivables, net315,848332,477
Investments—short-term324,295316,022
Inventory198,369186,406
Contract assets1,229706
Prepaid expenses and other current assets111,53998,166
Assets held for sale96,79294,260
Total current assets1,468,8251,485,506
PROPERTY, PLANT AND EQUIPMENT, NET224,590226,943
RIGHT-OF-USE ASSETS89,68391,460
INVESTMENTS—LONG-TERM62,78239,887
GOODWILL83,02783,027
INTANGIBLE ASSETS, NET9321,991
DEFERRED TAX ASSETS182,536195,888
OTHER ASSETS11,52111,521
TOTAL ASSETS2,123,8962,136,223
CURRENT LIABILITIES:  
Accounts payable and accrued expenses205,854240,561
Accrued sales discounts, allowances and reserves240,877263,641
Operating lease liabilities—short-term5,9105,746
Contract liabilities—short-term3,3362,730
Current portion of long-term debt3,0003,000
Liabilities related to discontinued operations 4,542
Total current liabilities458,977520,220
LONG-TERM DEBT287,095287,730
OPERATING LEASE LIABILITIES—LONG-TERM74,10275,709
OTHER LONG-TERM LIABILITIES48,95949,878
Total liabilities869,133933,537
COMMITMENTS AND CONTINGENT LIABILITIES (Note 16)
SHAREHOLDERS’ EQUITY:  
Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at March 31, 2024 and December 31, 2023
Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 175,734,220 and 172,569,051 shares issued; 169,184,516 and 166,979,833 shares outstanding at March 31, 2024 and December 31, 2023, respectively1,7571,726
Treasury shares, at cost (6,549,704 and 5,589,218 shares at March 31, 2024 and December 31, 2023, respectively)(217,685)(189,336)
Additional paid-in capital2,780,9922,736,934
Accumulated other comprehensive loss(3,601)(3,110)
Accumulated deficit(1,306,700)(1,343,528)
Total shareholders’ equity1,254,7631,202,686
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY$ 2,123,896$ 2,136,223
ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
 CEO
 WEBSITEalkermes.com
 INDUSTRYPharmaceuticals
 EMPLOYEES2280

Alkermes PLC Frequently Asked Questions


What is the ticker symbol for Alkermes PLC? What does ALKS stand for in stocks?

ALKS is the stock ticker symbol of Alkermes PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alkermes PLC (ALKS)?

As of Thu Jun 13 2024, market cap of Alkermes PLC is 4.2 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALKS stock?

You can check ALKS's fair value in chart for subscribers.

What is the fair value of ALKS stock?

You can check ALKS's fair value in chart for subscribers. The fair value of Alkermes PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alkermes PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALKS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alkermes PLC a good stock to buy?

The fair value guage provides a quick view whether ALKS is over valued or under valued. Whether Alkermes PLC is cheap or expensive depends on the assumptions which impact Alkermes PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALKS.

What is Alkermes PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, ALKS's PE ratio (Price to Earnings) is 9.66 and Price to Sales (PS) ratio is 2.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALKS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Alkermes PLC's stock?

In the past 10 years, Alkermes PLC has provided -0.062 (multiply by 100 for percentage) rate of return.